The company released preliminary H1 23 results, in line with our expectations.
Financing is secured for FY22 at least, with no dilutive instruments in sight.
Crossject will release more detailed numbers for H1 23 before the end of October.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
The company released preliminary H1 23 results, in line with our expectations.
Financing is secured for FY22 at least, with no dilutive instruments in sight.
Crossject will release more detailed numbers for H1 23 before the end of October.
